In vitro anti-inflammatory activity of ZnOTP and aspirina.
| Treatment | Concentration (μg mL−1) | Membrane stabilization activity (%) | Albumin denaturation inhibition (%) | Proteinase inhibition (%) |
|---|---|---|---|---|
| Control | — | — | — | — |
| ZnOTP | 25 | 25.2 ± 2.0* | 22.3 ± 0.6* | 30.1 ± 1.5* |
| ZnOTP | 50 | 38.6 ± 1.1* | 40.7 ± 1.1* | 48.3 ± 0.7* |
| ZnOTP | 100 | 49.4 ± 3.0* | 59.4 ± 0.6* | 60.2 ± 1.3* |
| ZnOTP | 200 | 60.7 ± 2.3* | 74.3 ± 1.3* | 77.3 ± 0.5* |
| ZnOTP | 400 | 78.4 ± 1.0* | 85.2 ± 1.1* | 88.4 ± 0.8* |
| Aspirin | 400 | 79.2 ± 0.4* | 86.5 ± 0.6* | 86.8 ± 1.3* |
a
Each value is reported as the mean ± SD (n = 3). Statistical significance was at p < 0.05 when compared to the control group. *p < 0.05.